Core Insights - The report highlights the accelerating competition and cooperation in advanced manufacturing between China and the US, particularly in the semiconductor, general aviation, and innovative pharmaceuticals sectors [6][11][18]. Semiconductor Industry - China is rapidly catching up in the semiconductor sector, focusing on self-sufficiency in AI chip production amidst a global supply chain heavily dominated by the US [2][19]. - The semiconductor industry has a complex global supply chain with multiple stages, where the US leads in high-value design and equipment, while China excels in manufacturing and testing [19][24]. - In terms of market share, China and the US together account for nearly 60% of global semiconductor sales, with the US holding a significant supply share of over 50% compared to China's less than 10% [22][24]. - China's semiconductor trade has been in a long-term deficit, with a projected deficit of $226.67 billion in 2024, while the US maintains a trade surplus of $10.25 billion [27][28]. - US semiconductor companies exhibit stronger fundamentals, with revenue and net profit significantly higher than their Chinese counterparts, and a return on equity (ROE) median approximately four times that of A-share companies [31][32]. General Aviation Industry - The US holds a first-mover advantage in the general aviation sector, while China is leveraging low-altitude economic policies to drive innovation and transformation [3][12]. - The global demand for general aviation aircraft is evenly distributed, with China and North America each accounting for about 20% of the market, but the US dominates supply with Boeing and Airbus [3][12]. - China's aerospace sector has a long-term trade deficit, while it is a leading exporter of drones [3][14]. - Current market performance shows that US aviation equipment companies outperform their Chinese counterparts in terms of scale and ROE [3][14]. Innovative Pharmaceuticals Industry - The US leads in the innovative pharmaceuticals sector, but Chinese companies are making significant strides in original innovation and international expansion [4][17]. - The pharmaceutical market share remains stable, with the US holding about 40% and China around 10%, primarily focusing on generic drugs [4][17]. - Both countries face trade deficits in pharmaceuticals, but Chinese innovative drug companies have accelerated their international presence, with increasing license-out revenues [4][19]. - US innovative pharmaceutical companies show better fundamentals, with many Chinese companies' valuations hovering around historical averages [4][20]. Market Outlook - The report anticipates a continuation of the mid-to-long-term technology market trends, with advanced manufacturing sectors like semiconductors, general aviation, and innovative pharmaceuticals presenting significant investment opportunities [7][18].